BioPharmSignal logoBioPharmSignal

Biotech News

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Centessa Pharmaceuticals (CNTA)Centessa PharmaceuticalsCompany update

Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today

Related news

CNTACentessa Pharmaceuticals2026-01-14 22:00 EST

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

CNTACentessa Pharmaceuticals2025-11-05 12:00 EST

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

View all latest news

Centessa Pharmaceuticals

Centessa Pharmaceuticals is a platform biopharma company incubating focused therapeutic programs across multiple disease areas. Its model emphasizes capital allocation, program selection, and broad platform optionality.

Recent company news

CNTACentessa Pharmaceuticals2026-03-31 10:45 EST

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

CNTACentessa Pharmaceuticals2026-02-03 13:00 EST

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

CNTACentessa Pharmaceuticals2026-01-14 22:00 EST

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

CNTACentessa Pharmaceuticals2025-12-11 12:00 EST

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

CNTACentessa Pharmaceuticals2025-11-12 01:40 EST

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Stock data

Close
40.50 USD
Market cap
6.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States